Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 3
Completed
NCT03088540
| Condition | Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma, Nonsmall Cell Lung Cancer |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Regeneron Pharmaceuticals |
|---|
| Status | Completed |
|---|
| Enrollment | 712 participants |
|---|
| Interventions | Pemetrexed, Paclitaxel, Gemcitabine, Cisplatin, Carboplatin |
|---|
| Start date | May 29, 2017 |
|---|
| Completion date | Apr 18, 2025 |
|---|
| Results posted | Jun 25, 2026 |
|---|
Summary
The primary objectives of the study are: * To compare the overall survival (OS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 in ≥50% of tumor cells * To compare the progression-free survival (PFS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic NSCLC whose tumors express PD-L1 in ≥50% of tumor cells The key secondary objective of the study is to compare the objective response rate (ORR) of cemiplimab versus platinum-based chemotherapies
Overall Survival (OS)
Up to 94 months · months
| Cemiplimab | 23.4 months |
|---|
| Chemotherapy | 13.7 months |
|---|
| p-value | <0.0001 |
|---|
| Hazard Ratio (HR) | 0.661 (95% CI 0.553–0.790) |
|---|
Progression-free Survival (PFS) Per Blinded IRC
Up to 94 months · months
| Cemiplimab | 6.3 months |
|---|
| Chemotherapy | 5.3 months |
|---|
| p-value | <0.0001 |
|---|
| Hazard Ratio (HR) | 0.559 (95% CI 0.469–0.665) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.